Mol. Cells 2019; 42(2): 161~165

TGFBI Promoter Methylation is Associated with Poor Prognosis in Lung Adenocarcinoma Patients

Yangki Seok1, Won Kee Lee2, Jae Yong Park3,*, and Dong Sun Kim4,*

1Departments of Thoracic Surgery, 2Preventive Medicine, 3Internal Medicine, 4Anatomy, School of Medicine, Kyungpook National University, Daegu 702-422, Korea

*Correspondence: (JYP); (DSK)
Received July 30, 2018; Revised November 1, 2018; Accepted December 10, 2018.; Published online January 24, 2019.
© Korean Society for Molecular and Cellular Biology. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit (
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide and has high rates of metastasis. Transforming growth factor beta-inducible protein (TGFBI) is an extracellular matrix component involved in tumour growth and metastasis. However, the exact role of TGFBI in NSCLC remains controversial. Gene silencing via DNA methylation of the promoter region is common in lung tumorigenesis and could thus be used for the development of molecular biomarkers. We analysed the methylation status of the TGFBI promoter in 138 NSCLC specimens via methylationspecific PCR and evaluated the correlation between TGFBI methylation and patient survival. TGFBI promoter methylation was detected in 25 (18.1%) of the tumours and was demonstrated to be associated with gene silencing. We observed no statistical correlation between TGFBI methylation and clinicopathological characteristics. Univariate and multivariate analyses showed that TGFBI methylation is significantly associated with poor survival outcomes in adenocarcinoma cases (adjusted hazard ratio = 2.88, 95% confidence interval = 1.19-6.99, P = 0.019), but not in squamous cell cases. Our findings suggest that methylation in the TGFBI promoter may be associated with pathogenesis of NSCLC and can be used as a predictive marker for lung adenocarcinoma prognosis. Further large-scale studies are needed to confirm these findings.
Keywords: Hypermethylation, MSP, NSCLC, Prognosis, TGFBI

Current Issue

30 April 2019 Volume 42,
Number 4, pp. 285~377

This Article

Cited By Articles
  • CrossRef (0)

Social Network Service

Indexed in

  • Science Central
  • CrossMark